| __timestamp | Agios Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 205018000 |
| Thursday, January 1, 2015 | 141827000 | 392709000 |
| Friday, January 1, 2016 | 220163000 | 299694000 |
| Sunday, January 1, 2017 | 292681000 | 397061000 |
| Monday, January 1, 2018 | 1397000 | 434100000 |
| Tuesday, January 1, 2019 | 1317000 | 782200000 |
| Wednesday, January 1, 2020 | 2805000 | 1119900000 |
| Friday, January 1, 2021 | 18777000 | 2437500000 |
| Saturday, January 1, 2022 | 1704000 | 1560400000 |
| Sunday, January 1, 2023 | 9504000 | 1815800000 |
| Monday, January 1, 2024 | 4165000 | 1970500000 |
Data in motion
In the competitive world of biotechnology, understanding cost structures is crucial. Regeneron Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Regeneron's cost of revenue surged by over 780%, peaking at approximately $1.82 billion in 2023. This reflects their aggressive expansion and robust product pipeline. In contrast, Agios Pharmaceuticals experienced a more volatile journey, with costs fluctuating significantly, peaking in 2017 and then dropping sharply. By 2023, Agios's cost of revenue was a mere fraction of Regeneron's, highlighting their strategic pivot towards more niche markets. This comparison underscores the diverse strategies within the biotech sector, where scale and specialization can both lead to success. As the industry evolves, these companies' financial strategies will continue to shape their competitive landscapes.
Cost of Revenue Trends: AstraZeneca PLC vs Agios Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Walgreens Boots Alliance, Inc.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Corcept Therapeutics Incorporated's Expenses
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Alkermes plc
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs MorphoSys AG
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Evotec SE's Expenses
Cost of Revenue Comparison: GSK plc vs Agios Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Sarepta Therapeutics, Inc. and Agios Pharmaceuticals, Inc.
Cost of Revenue Trends: ADMA Biologics, Inc. vs Agios Pharmaceuticals, Inc.
Analyzing Cost of Revenue: MorphoSys AG and Agios Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Mesoblast Limited vs Agios Pharmaceuticals, Inc.